RAICHUR, Indien, 13. März 2025 /PRNewswire/ -- Shilpa Medicare Limited (BSE: 530549) (NSE: SHILPAMED), ein führender Hersteller von Wirkstoffen und Formulierungen, gibt bekannt, dass der Sachverständigenausschuss (SEC) der CDSCO sein neues Prüfpräparat (Investigational New Drug, IND) –...
Hence then, the article about shilpa medicare sichert sich sec cdsco nod fur nor ursodeoxycholsaure tabletten und strebt markteinfuhrung fur nash an was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Shilpa Medicare sichert sich SEC-CDSCO Nod für Nor-Ursodeoxycholsäure-Tabletten und strebt Markteinführung für NASH an )
Also on site :
- Dispatch centers in Marin County down, service outage reported for 911 calls
- Hawaiian Airlines announces Kahu'ewai Hawai'i Investment Plan of more than $600M over five years to modernize infrastructure and guest experience, and deepen its commitment to the community and sustainability
- Flutterwave buys Nigeria’s Mono in rare African fintech exit